The effect of low-dose atorvastatin on circulating monocyte chemoattractant protein–1 in patients with type 2 diabetes complicated by hyperlipidemia

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

Helen M. Colhoun, D. J. Betteridge, Paul N. Durrington et al. · The Lancet · 2004 · 3.8K citations

Medicine, Pharmacotherapy, Preventive Medicine +9

Effect of Statin Therapy on C-Reactive Protein Levels

Michelle A. Albert, Ellie Danielson, Nader Rifai et al. · JAMA · 2001 · 1.7K citations

Medicine, Pharmacology, Pharmacotherapy +12

Activation of interleukin-6 gene expression through the NF-kappa B transcription factor.

Towia A. Libermann, David Baltimore · Molecular and Cellular Biology · 1990 · 1.4K citations

Life Sciences, Cell Biology, Molecular Biology +16

NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X

John C. Pickup, M. Mattock, Gary Chusney et al. · Diabetologia · 1997 · 1.2K citations · Full text

Veterinary Medicine, Immunology, Internal Medicine +16

Monocyte chemoattractant protein-1 in human atheromatous plaques.

N A Nelken, Shaun R. Coughlin, David J. Gordon et al. · Journal of Clinical Investigation · 1991 · 886 citations · Full text

Life Sciences, Cardiology, Cell Biology +15